Therefore, considering that RVX‐208 could mimic hAPOA1 effect and to test whether it could be included as a complementary treatment for CRC patients, we analyzed whether ABCA1‐dependent malignant features could be ameliorated by the RVX‐208 mechanism of action. The gene discussed is ABCA1; the disease is colorectal carcinoma.